← Back to Search

Cannabinoid

Delta-9-Tetrahydrocannabinol's (Delta-9-THC) effects on pain for Fibromyalgia

Q: Which members of the population are qualified to participate in this investigation?

Eligibility for this trial necessitates that applicants suffer from <a href="https://www.withpower.com/clinical-trials/chronic-pain">chronic pain</a>, be of adult age (18-50), and uniformly experience symptoms. Altogether, 75 participants are sought after.

Q: How many participants can potentially join this clinical trial?

Indeed, as evidenced by the information on clinicaltrials.gov, this medical study is currently in pursuit of participants. It was initially published on February 1st 2018 and has undergone its most recent update on March 8th 2022. Furthermore, it requires 75 patients to be recruited from a single site.

Q: Are there any other reports that examine the potential of CBD to help with pain symptoms?

Currently, 104 medical studies are being conducted to analyze the effects of Cannabidiol (<a href="https://www.withpower.com/clinical-trials/cbd">CBD</a>) on <a href="https://www.withpower.com/clinical-trials/pain-management">pain management</a>. Nineteen trials have already entered Phase 3 and Belmont, <a href="https://www.withpower.com/clinical-trials/massachusetts">Massachusetts</a> is a major hub for this research with 331 worldwide locations running related tests.

Q: Is this research currently recruiting participants?

Evidenced by recent edits on clinicaltrials.gov, this study is actively seeking volunteers for participation. The trial was initially posted in February of 2018 and its information has been amended most recently in March of 2022.

Q: Is there an upper limit for eligibility in this trial?

Eligibility for this trial requires that the patient's age falls between 18 and 50 years old.

Q: What disorders and symptoms are typically alleviated through Cannabidiol (CBD) therapy?

<a href="https://www.withpower.com/clinical-trials/cbd">CBD</a> is typically prescribed as a supplemental treatment for those who do not respond to standard therapies. In addition, it has been used to manage symptoms associated with <a href="https://www.withpower.com/clinical-trials/multiple-sclerosis">multiple sclerosis</a>, pharmacotherapy and <a href="https://www.withpower.com/clinical-trials/pain">pain</a>-related symptoms.

Phase < 1

Recruiting

Led By Deborah Yurgelun-Todd, Ph.D.

Research Sponsored by University of Utah

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Chronic musculoskeletal and joint pain for at least 3 months or longer

Age between 18-50 yrs

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 7 days

Awards & highlights

Study Summary

This trial looks at whether THC, CBD, or a placebo can help with chronic non-cancer pain.

Who is the study for?

This trial is for adults aged 18-50 with a history of cannabis use who suffer from chronic musculoskeletal and joint pain lasting at least 3 months. Participants must live within 60 miles of Salt Lake City, Utah.Check my eligibility

What is being tested?

The study compares the effects on chronic non-cancer pain between three options: Delta-9-Tetrahydrocannabinol (THC), Cannabidiol (CBD), and a placebo to see which is more effective in managing pain.See study design

What are the potential side effects?

Potential side effects may include dizziness, dry mouth, changes in appetite or mood, fatigue, and possibly altered mental state due to THC's psychoactive properties.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have had joint or muscle pain for 3 months or more.

Select...

I am between 18 and 50 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 7 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~7 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Brain

Secondary outcome measures

Pain

Other outcome measures

Neurocognitive performance

Trial Design

3Treatment groups

Active Control

Placebo Group

Group I: Delta-9-Tetrahydrocannabinol's (Delta-9-THC) effects on painActive Control1 Intervention

This arm will be testing the analgesic effects of orally dosed Delta-9-Tetrahydrocannabinol on subjects with chronic non-cancer pain.

Group II: Cannabidiol's (CBD) effects on painActive Control1 Intervention

This arm will be testing the analgesic effects of orally dosed Cannabidiol on subjects with chronic non-cancer pain.

Group III: PlaceboPlacebo Group1 Intervention

This Placebo arm will act as the control as standard of care medications will be continued through the study. This arm will allow us to compare the analgesic effects of the other two arms with the standard of care treatments for chronic non-cancer pain.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of UtahLead Sponsor

1,103 Previous Clinical Trials

1,781,642 Total Patients Enrolled

6 Trials studying Fibromyalgia

512 Patients Enrolled for Fibromyalgia

Deborah Yurgelun-Todd, Ph.D.Principal Investigator - University of Utah Brain Institute

University of Utah

1 Previous Clinical Trials

68 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which members of the population are qualified to participate in this investigation?

"Eligibility for this trial necessitates that applicants suffer from chronic pain, be of adult age (18-50), and uniformly experience symptoms. Altogether, 75 participants are sought after."

Answered by AI

How many participants can potentially join this clinical trial?

"Indeed, as evidenced by the information on clinicaltrials.gov, this medical study is currently in pursuit of participants. It was initially published on February 1st 2018 and has undergone its most recent update on March 8th 2022. Furthermore, it requires 75 patients to be recruited from a single site."

Answered by AI

Are there any other reports that examine the potential of CBD to help with pain symptoms?

"Currently, 104 medical studies are being conducted to analyze the effects of Cannabidiol (CBD) on pain management. Nineteen trials have already entered Phase 3 and Belmont, Massachusetts is a major hub for this research with 331 worldwide locations running related tests."

Answered by AI

Is this research currently recruiting participants?

"Evidenced by recent edits on clinicaltrials.gov, this study is actively seeking volunteers for participation. The trial was initially posted in February of 2018 and its information has been amended most recently in March of 2022."

Answered by AI

Is there an upper limit for eligibility in this trial?

"Eligibility for this trial requires that the patient's age falls between 18 and 50 years old."

Answered by AI

What disorders and symptoms are typically alleviated through Cannabidiol (CBD) therapy?

"CBD is typically prescribed as a supplemental treatment for those who do not respond to standard therapies. In addition, it has been used to manage symptoms associated with multiple sclerosis, pharmacotherapy and pain-related symptoms."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)

Deborah Yurgelun-Todd 2018. "Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03215940.

All > American Chronic Pain > Epidiolex